- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Sexual Dysfunction
- Interventions
- Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–282
of 282
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Interferon beta-1a, Alemtuzumab 12 mg, Alemtuzumab 24 mg
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 31
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 27 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Intermittent fasting
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Ozanimod, Fingolimod, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2036
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Sacramento, California • Tampa, Florida + 8 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Plovamer acetate 0.5 milligram (mg), Copaxone 20 mg, Plovamer acetate 3 mg, Plovamer acetate 10 mg, Plovamer acetate 20 mg
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 35
- States / cities
- Redding, California • San Diego, California • Fairfield, Connecticut + 30 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- LY2127399, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 24 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Teriflunomide
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- 19 nor vitamin d
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 45 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Transverse Myelitis
- Interventions
- Not listed
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Relapse-Remitting Multiple Sclerosis
- Interventions
- glatiramer acetate 20 mg, glatiramer acetate 40 mg
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 20
- States / cities
- La Jolla, California • Oceanside, California • Atlanta, Georgia + 17 more
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Swank Diet, Wahls Elimination Diet
- Behavioral
- Lead sponsor
- Terry L. Wahls
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis
- Interventions
- dimethyl fumarate
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 15
- States / cities
- Gilbert, Arizona • Long Beach, California • Ocala, Florida + 11 more
- Conditions
- Multiple Sclerosis
- Interventions
- HB-adMSCs, Placebo
- Biological · Drug
- Lead sponsor
- Hope Biosciences Research Foundation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Sugar Land, Texas
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- GA Depot, Placebo
- Drug · Other
- Lead sponsor
- Mapi Pharma Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,016 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Pasadena, California + 8 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- dimethyl fumarate, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 19 Years to 58 Years
- Enrollment
- 1,736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 44 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Inosine
- Drug
- Lead sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Relapse Remitting Multiple Sclerosis
- Interventions
- Blood Draw
- Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Tovaxin Autologous T cell vaccine, Placebo
- Biological
- Lead sponsor
- Opexa Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 33
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 29 more